TKP-AII-11

TKP-AII-11 is an 18F-labeled antibody fragment developed by TheraCea Pharma as a positron emission tomography (PET) imaging radiotracer. It is specifically designed for the detection and monitoring of breast cancer. The agent utilizes TheraCea's proprietary platform technology for the efficient and site-specific incorporation of Fluorine-18 into antibody fragments, which are intended to target specific biomarkers associated with breast cancer. This approach aims to provide high-contrast imaging for early diagnosis and the assessment of therapeutic response by leveraging the favorable pharmacokinetics of antibody fragments, such as rapid blood clearance and high tissue penetration.